Does the media refer more to VYGR or ACRS?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Aclaris Therapeutics and 7 mentions for Voyager Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.26 beat Voyager Therapeutics' score of 0.14 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to VYGR or MNPR?

In the previous week, Voyager Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Voyager Therapeutics' score of 0.14 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AURA or VYGR?

In the previous week, Voyager Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.70 beat Voyager Therapeutics' score of 0.14 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PHAR or VYGR?

In the previous week, Pharming Group had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 7 mentions for Voyager Therapeutics. Pharming Group's average media sentiment score of 0.32 beat Voyager Therapeutics' score of 0.14 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer DRUG or VYGR?

In the previous week, Voyager Therapeutics had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat Voyager Therapeutics' score of 0.14 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Voyager Therapeutics (VYGR) Competitors

$3.17 -0.10 (-3.06%)

As of 04:00 PM Eastern

Compare

VYGR vs. ACRS, MNPR, AURA, PHAR, and DRUG

Should you buy Voyager Therapeutics stock or one of its competitors? Voyager Therapeutics's main competitors and comparable companies include Aclaris Therapeutics (ACRS), Monopar Therapeutics (MNPR), Aura Biosciences (AURA), Pharming Group (PHAR), and Bright Minds Biosciences (DRUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Aclaris Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A
Aclaris Therapeutics	$7.83M	105.36	-$64.92M	-$0.58	N/A

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 420.50%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 94.92%. Given Voyager Therapeutics' higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Voyager Therapeutics has a net margin of -312.63% compared to Aclaris Therapeutics' net margin of -921.50%. Voyager Therapeutics' return on equity of -54.82% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-54.82%	-42.53%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Aclaris Therapeutics and 7 mentions for Voyager Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.26 beat Voyager Therapeutics' score of 0.14 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Voyager Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Voyager Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Monopar Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Monopar Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Monopar Therapeutics' return on equity of -12.84% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-54.82%	-42.53%
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, Voyager Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.47 beat Voyager Therapeutics' score of 0.14 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 420.50%. Monopar Therapeutics has a consensus price target of $112.08, indicating a potential downside of 3.67%. Given Voyager Therapeutics' higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Summary

Monopar Therapeutics beats Voyager Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Voyager Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 166.23%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 420.50%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aura Biosciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -54.82% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Voyager Therapeutics	-312.63%	-54.82%	-42.53%

In the previous week, Voyager Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.70 beat Voyager Therapeutics' score of 0.14 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Aura Biosciences has higher earnings, but lower revenue than Voyager Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Summary

Voyager Therapeutics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Voyager Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Pharming Group currently has a consensus price target of $38.67, suggesting a potential upside of 240.68%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 420.50%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Pharming Group has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.14	$2.85M	$0.12	94.58
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Pharming Group has a net margin of 2.51% compared to Voyager Therapeutics' net margin of -312.63%. Pharming Group's return on equity of 3.40% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Voyager Therapeutics	-312.63%	-54.82%	-42.53%

In the previous week, Pharming Group had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 7 mentions for Voyager Therapeutics. Pharming Group's average media sentiment score of 0.32 beat Voyager Therapeutics' score of 0.14 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Pharming Group beats Voyager Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Voyager Therapeutics compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Bright Minds Biosciences has a beta of -5.27, meaning that its share price is 627% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Bright Minds Biosciences' return on equity of -20.58% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Voyager Therapeutics	-312.63%	-54.82%	-42.53%

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Voyager Therapeutics had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Voyager Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.29 beat Voyager Therapeutics' score of 0.14 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Bright Minds Biosciences has higher earnings, but lower revenue than Voyager Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Voyager Therapeutics	$40.37M	4.74	-$119.72M	-$1.80	N/A

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 78.03%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 420.50%. Given Voyager Therapeutics' higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Bright Minds Biosciences beats Voyager Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYGR vs. The Competition

Export

Metric	Voyager Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$191.53M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.76	9.13	269.75	24.74
Price / Sales	4.74	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.90	17.66	11.27	6.42
Net Income	-$119.72M	-$13.25M	$3.45B	$347.12M
7 Day Performance	5.67%	5.36%	3.56%	2.48%
1 Month Performance	-7.85%	-1.74%	-0.58%	-1.04%
1 Year Performance	0.96%	61.36%	77.52%	23.22%

Voyager Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYGR Voyager Therapeutics	2.7123 of 5 stars	$3.17 -3.1%	$16.50 +420.5%	+4.1%	$191.53M	$40.37M	N/A	100	Earnings Report Analyst Forecast
ACRS Aclaris Therapeutics	2.1048 of 5 stars	$5.53 +6.3%	$11.50 +108.0%	+262.6%	$726.25M	$7.83M	N/A	100	Positive News Earnings Report
MNPR Monopar Therapeutics	1.2663 of 5 stars	$111.64 +3.0%	$112.08 +0.4%	+244.0%	$725.84M	N/A	N/A	10	Upcoming Earnings Analyst Upgrade
AURA Aura Biosciences	2.9609 of 5 stars	$7.04 +0.4%	$20.50 +191.2%	+17.5%	$724.74M	N/A	N/A	50	Upcoming Earnings Analyst Upgrade
PHAR Pharming Group	3.7315 of 5 stars	$9.82 -2.6%	$38.67 +293.8%	-18.0%	$713.44M	$376.13M	81.83	280	Analyst Forecast Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYGR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Voyager Therapeutics (VYGR) Competitors

VYGR vs. ACRS, MNPR, AURA, PHAR, and DRUG

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Summary

How does Voyager Therapeutics compare to Monopar Therapeutics?

Summary

How does Voyager Therapeutics compare to Aura Biosciences?

Summary

How does Voyager Therapeutics compare to Pharming Group?

Summary

How does Voyager Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Voyager Therapeutics (VYGR) Competitors

VYGR vs. ACRS, MNPR, AURA, PHAR, and DRUG

How does Voyager Therapeutics compare to Aclaris Therapeutics?

Which has better valuation & earnings, VYGR or ACRS?

Do analysts recommend VYGR or ACRS?

Is VYGR or ACRS more profitable?

Do insiders and institutionals believe in VYGR or ACRS?

Does the media refer more to VYGR or ACRS?

Which has more volatility & risk, VYGR or ACRS?

Summary

How does Voyager Therapeutics compare to Monopar Therapeutics?

Is VYGR or MNPR more profitable?

Does the media refer more to VYGR or MNPR?

Do institutionals & insiders believe in VYGR or MNPR?

Do analysts rate VYGR or MNPR?

Which has more volatility & risk, VYGR or MNPR?

Which has better earnings & valuation, VYGR or MNPR?

Summary

How does Voyager Therapeutics compare to Aura Biosciences?

Do analysts prefer AURA or VYGR?

Is AURA or VYGR more profitable?

Does the media prefer AURA or VYGR?

Which has stronger earnings and valuation, AURA or VYGR?

Do insiders and institutionals hold more shares of AURA or VYGR?

Which has more risk & volatility, AURA or VYGR?

Summary

How does Voyager Therapeutics compare to Pharming Group?

Do analysts prefer PHAR or VYGR?

Which has better valuation and earnings, PHAR or VYGR?

Do institutionals & insiders hold more shares of PHAR or VYGR?

Which has more risk and volatility, PHAR or VYGR?

Is PHAR or VYGR more profitable?

Does the media prefer PHAR or VYGR?

Summary

How does Voyager Therapeutics compare to Bright Minds Biosciences?

Which has more volatility and risk, DRUG or VYGR?

Is DRUG or VYGR more profitable?

Do institutionals and insiders hold more shares of DRUG or VYGR?

Does the media prefer DRUG or VYGR?

Which has higher earnings & valuation, DRUG or VYGR?

Do analysts prefer DRUG or VYGR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR vs. The Competition

Voyager Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools